[1]CurrentPatentAssignee:H.LUNDBECKA/S-WO2008/113359,2008,A2Locationinpatent:Page/Pagecolumn15
[2]CurrentPatentAssignee:NI&CO.-US2016/200698,2016,A1Locationinpatent:Paragraph0173;0174;0175
[3]CurrentPatentAssignee:JEWIMPHARMACEUTICALSHANDONG-CN110105309,2019,ALocationinpatent:Paragraph0086
[4]CurrentPatentAssignee:ZHONGSHANWANYUANNEWDRUGDEV;ZHONGSHANWANHANPHARMACY-CN108047162,2018,ALocationinpatent:Paragraph0048;0049
[5]CurrentPatentAssignee:NOVARTISAG;Sandoz(in:Novartis)-WO2015/833,2015,A1Locationinpatent:Page/Pagecolumn23
[6]CurrentPatentAssignee:H.LUNDBECKA/S-US9475748,2016,B2Locationinpatent:Page/Pagecolumn14
[7]CurrentPatentAssignee:NI&CO.-CN104736526,2016,BLocationinpatent:Paragraph0181
[8]CurrentPatentAssignee:H.LUNDBECKA/S-WO2007/144005,2007,A1Locationinpatent:Page/Pagecolumn28-29
[1]CurrentPatentAssignee:NI&CO.-US2016/200698,2016,A1Locationinpatent:Paragraph0207;0208
[2]CurrentPatentAssignee:ENANTIASL-WO2018/224594,2018,A1Locationinpatent:Page/Pagecolumn13;14
[3]CurrentPatentAssignee:HANGZHOUHEKANGPHARMACEUTICAL-CN110790727,2020,ALocationinpatent:Paragraph0043-0061
[4]CurrentPatentAssignee:ZHUHAIANBAOJIANPHARMACEUTICAL-CN113563285,2021,ALocationinpatent:Paragraph0025-0028;0031-0036
[5]CurrentPatentAssignee:YANGTZERIVERPHARMACEUTICALGROUPCOLTD-CN105017176,2017,BLocationinpatent:Paragraph0035;0036;0037;0038;0039;0040
[6]CurrentPatentAssignee:YANGTZERIVERPHARMACEUTICALGROUPCOLTD-CN104910099,2017,BLocationinpatent:Paragraph0039;0040;0041;0042;0043;0044
[7]CurrentPatentAssignee:Sandoz(in:Novartis);NOVARTISAG-WO2014/161976,2014,A1Locationinpatent:Page/Pagecolumn17;18
[8]CurrentPatentAssignee:Sandoz(in:Novartis);NOVARTISAG-WO2014/191548,2014,A1Locationinpatent:Page/Pagecolumn27;28
[9]CurrentPatentAssignee:Sandoz(in:Novartis);NOVARTISAG-WO2015/107057,2015,A1Locationinpatent:Page/Pagecolumn2015
[10]CurrentPatentAssignee:NOVARTISAG;Sandoz(in:Novartis)-WO2015/155153,2015,A1Locationinpatent:Page/Pagecolumn18
[11]CurrentPatentAssignee:XINCHANGKANGLECHEMICALSCO.,LTD.-CN110372635,2019,ALocationinpatent:Paragraph0050-0057;0061-0086
[12]CurrentPatentAssignee:BEIJINGLABWORLDBIOMEDICALTECHNOLOGYCOLTD-CN104119298,2016,BLocationinpatent:Paragraph0240;0241
[13]CurrentPatentAssignee:DIPHARMAFRANCISS.R.L.-US2016/145224,2016,A1Locationinpatent:Paragraph0084-0085
[14]CurrentPatentAssignee:AMNEALPHARMACEUTICALSLLC-WO2017/29377,2017,A1Locationinpatent:Page/Pagecolumn46
[15]CurrentPatentAssignee:CHENGDUHONGDAPHARMACEUTICALCOLTD-CN106316986,2017,ALocationinpatent:Paragraph0066;0067;0068;0069;0070;0071;0072-0092
[16]CurrentPatentAssignee:CHENGDUHONGDAPHARMACEUTICALCOLTD-CN110156720,2019,ALocationinpatent:Paragraph0058-0061;0082;0083
[17]CurrentPatentAssignee:CHENGDUHONGDAPHARMACEUTICALCOLTD-CN109928941,2019,ALocationinpatent:Paragraph0031-0034
[18]CurrentPatentAssignee:ZHENGZHOUDAMINGDRUGSCIENCE&TECHNOLOGYCO.,LTD.-CN104725335,2017,BLocationinpatent:Paragraph0031;0032;0033;0034;0035;0042;0043-0045
[19]CurrentPatentAssignee:H.LUNDBECKA/S-WO2007/144005,2007,A1Locationinpatent:Page/Pagecolumn29
[20]CurrentPatentAssignee:H.LUNDBECKA/S-WO2008/113359,2008,A2Locationinpatent:Page/Pagecolumn16
[21]CurrentPatentAssignee:SHANGHAIBOCIMEDPHARMACEUTICALCOLTD-CN108191792,2018,ALocationinpatent:Paragraph0163-0165
[22]CurrentPatentAssignee:SERVIERMONDE-WO2015/114395,2015,A1Locationinpatent:Page/Pagecolumn43
[23]CurrentPatentAssignee:SHANDONGLUNINGPHARMACEUTICAL-CN107266390,2017,ALocationinpatent:Paragraph0025;0026
[24]CurrentPatentAssignee:H.LUNDBECKA/S-WO2010/94285,2010,A1Locationinpatent:Page/Pagecolumn10
[25]CurrentPatentAssignee:H.LUNDBECKA/S-WO2007/144005,2007,A1Locationinpatent:Page/Pagecolumn29-30
[26]CurrentPatentAssignee:H.LUNDBECKA/S-WO2008/113359,2008,A2Locationinpatent:Page/Pagecolumn16-17
[27]CurrentPatentAssignee:LAKSHMIPRASAD,Alaparthi;SADASIVARAO,Ginjupalli;MURALIKRISHNA,Madala;ANAND,Mantri;UDAY,Sharma-WO2017/216805,2017,A1Locationinpatent:Page/Pagecolumn11;15
[28]CurrentPatentAssignee:SHANGHAINEOSUNPHARMACEUTICALTECHNOLOGY-CN105330614,2016,ALocationinpatent:Paragraph0025;0026;0027
[29]CurrentPatentAssignee:VIATRISINC-WO2016/125191,2016,A2Locationinpatent:Page/Pagecolumn35
[30]CurrentPatentAssignee:BEIJINGLABWORLDBIOMEDICALTECHNOLOGYCOLTD-CN104119299,2016,BLocationinpatent:Paragraph0239;0240;0241;0242
[31]CurrentPatentAssignee:MSNLABORATORIESPRIVATELIMITED-WO2017/154016,2017,A1Locationinpatent:Page/Pagecolumn15
[32]CurrentPatentAssignee:H.LUNDBECKA/S-WO2007/144005,2007,A1Locationinpatent:Page/Pagecolumn46-48
[33]CurrentPatentAssignee:H.LUNDBECKA/S-WO2007/144005,2007,A1Locationinpatent:Page/Pagecolumn48-50
[34]CurrentPatentAssignee:H.LUNDBECKA/S-WO2008/113359,2008,A2
[35]CurrentPatentAssignee:JEWIMPHARMACEUTICALSHANDONG-CN110105309,2019,ALocationinpatent:Paragraph0085
[36]CurrentPatentAssignee:H.LUNDBECKA/S-EP2219647,2020,B2Locationinpatent:Paragraph0059;0061
[37]CurrentPatentAssignee:BEIJINGZHENLVTIANYUANTECH-CN113501795,2021,ALocationinpatent:Paragraph0033;0035;0037-0040;0042;0044;0050;0052;...
[1]CurrentPatentAssignee:H.LUNDBECKA/S-WO2007/144005,2007,A1Locationinpatent:Page/Pagecolumn31-32
[2]CurrentPatentAssignee:H.LUNDBECKA/S-WO2008/113359,2008,A2Locationinpatent:Page/Pagecolumn18-19
[3]CurrentPatentAssignee:H.LUNDBECKA/S-WO2007/144005,2007,A1Locationinpatent:Page/Pagecolumn31-32
[4]CurrentPatentAssignee:VIATRISINC-WO2016/125191,2016,A2Locationinpatent:Page/Pagecolumn35
[5]CurrentPatentAssignee:ZHEJIANGUNIVERSITY-CN105153066,2018,BLocationinpatent:Paragraph0100-0117
[1]CurrentPatentAssignee:H.LUNDBECKA/S-WO2007/144005,2007,A1Locationinpatent:Page/Pagecolumn33
[2]CurrentPatentAssignee:H.LUNDBECKA/S-WO2008/113359,2008,A2Locationinpatent:Page/Pagecolumn20
[1]CurrentPatentAssignee:H.LUNDBECKA/S-WO2007/144005,2007,A1Locationinpatent:Page/Pagecolumn34-35
[2]CurrentPatentAssignee:H.LUNDBECKA/S-WO2008/113359,2008,A2Locationinpatent:Page/Pagecolumn21
Title: Vortioxetine exerts anti-inflammatory and immunomodulatory effects on human monocytes/macrophages.
Journal: British journal of pharmacology 20180101
Title: 5-HTT and 5-HT(1A) receptor occupancy of the novel substance vortioxetine (Lu AA21004). A PET study in control subjects.
Journal: European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20131001
Title: Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats.
Journal: Pharmacology, biochemistry, and behavior 20130401
Title: A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD).
Journal: European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20120701
Title: Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20120701
Title: A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder.
Journal: International clinical psychopharmacology 20120701
Title: A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder.
Journal: The international journal of neuropsychopharmacology 20120601
Title: Occupancy of the serotonin transporter after administration of Lu AA21004 and its relation to plasma concentration in healthy subjects.
Journal: Basic & clinical pharmacology & toxicology 20120401
Title: Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder.
Journal: The Journal of pharmacology and experimental therapeutics 20120301
Title: Biosynthesis and identification of an N-oxide/N-glucuronide metabolite and first synthesis of an N-O-glucuronide metabolite of Lu AA21004.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20111201
Title: Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.
Journal: Journal of medicinal chemistry 20110512
Title: Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.
Journal: IDrugs : the investigational drugs journal 20101201
Title: Synthesis and structure--activity relationship in a class of indolebutylpiperazines as dual 5-HT(1A) receptor agonists and serotonin reuptake inhibitors.
Journal: Journal of medicinal chemistry 20040909
Title: Bang-Andersen B, Ruhland T, J?rgensen M, Discovery of 1--(2,4-dimethylphenylsulfanyl)phenylpiperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011 May 12;54(9):3206-21.
Title: Guilloux JP, Mendez-David I, Pehrson A, Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice. Neuropharmacology. 2013 May 28;73C:147-159.
Title: Theunissen EL, Street D, H?jer AM, A randomized trial on the acute and steady-state effects of a new antidepressant, vortioxetine (Lu AA21004), on actual driving and cognition. Clin Pharmacol Ther. 2013 Jun;93(6):493-501.
Title: Rothschild AJ, Mahableshwarkar AR, Jacobsen P, Vortioxetine (Lu AA21004) 5mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States. Eur Neuropsychopharmacol. 2012 Dec;22(12):858-66.
Title: M?rk A, Pehrson A, Brennum LT, Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther. 2012 Mar;340(3):666-75.
